The Science and Technology Committee inquiry into ‘genomics and genome editing in the NHS’ carries forward the previous Committee’s inquiry into ‘genomics and genome editing’. This session aims to focus on issues arising from the Chief Medical Officer’s annual report and the Life Science Industrial Strategy, both published this summer
Wednesday 1 November 2017, Committee Room 6, Palace of Westminster
- Dr Magdalini Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry
- Professor Sir John Bell, Regius Professor of Medicine, University of Oxford
At 3.30 pm
- Dr Mark Kroese, Chair, Diagnostics Advisory Committee, National Institute for Health and Care Excellence
- Professor Sue Hill, Chief Scientific Officer for England, NHS England
- Professor William Newman, Vice Chair, British Society for Genetic Medicine
Purpose of the session
The first panel will discuss the CMO’s report and the Life Sciences Industrial Strategy from industry’s point of view. It will review the potential for genomics and genome editing, NHS engagement with industry and regulatory challenges.
The second panel will examine current plans and potential challenges involved in making genomics a routine part of NHS care and realising the Chief Medical Officer’s ‘genomic dream’. It will aim to evaluate evidence from the 100,000 Genomes Project, and cover patient welfare, costs, infrastructure and NHS workforce skills going forward.
Image: CC0 Creative Commons